-
Masahisa KATSUNO
Department of Neurology, Nagoya University Graduate School of Medicine
-
Atsushi HASHIZUME
Department of Neurology, Nagoya University Graduate School of Medicine
-
Harumasa NAKAMURA
Clinical Research Support Office, Translational Medical Center, National Center of Neurology and Psychiatry
-
Kenjiro ONO
Department of Internal Medicine, Division of Neurology, School of Medicine, Showa University
-
Koichiro YUJI
Project Division of International Advanced Medical Research, the Institute of Medical Science, the University of Tokyo
-
Masanobu YAMADA
Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare
-
Takuya WATANABE
Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare
-
Katsuhiko ICHIMARU
Office of New Drug III, Pharmaceuticals and Medical Devices Agency (PMDA)
-
Naoto KATO
Office of New Drug III, Pharmaceuticals and Medical Devices Agency (PMDA)
-
Takahiro INOUE
Division of Drug Research, Department of Research Promotion Japan Agency for Medical Research and Development (AMED)
-
Makiko KUSAMA
Division of Drug Research, Department of Research Promotion Japan Agency for Medical Research and Development (AMED)
-
Hiroshi MIZUSHIMA
Center for Public Health Informatics, National Institute of Public Health
-
Yoko FUJIMOTO
Medical Affairs PEH, Pfizer Japan Inc.
-
Makoto AKIMOTO
Clinical Research Planning and Coordination Department I, Mitsubishi Tanabe Pharma Corporation
-
Kiyoshi KOBAYASHI
Translational Medicine, Development Division, Novartis Pharma K.K.
-
Kenji OHWAKI
PhRMA Translational Research Subcommittee Diabetes Products, Medicines Development Unit Japan, Eli Lilly Japan K.K.
-
Koji UESUGI
PhRMA Translational Research Subcommittee Regulatory Policy, Regulatory Affairs, Pfizer Japan Inc.
